# BAT

NDC: 60492-0075
Generic name: Botulism Antitoxin Heptavalent
Labeler / Manufacturer: Emergent BioSolutions Canada Inc
Product type: PLASMA DERIVATIVE
Marketing category: Biologic License Application
Dosage form: LIQUID
Routes: INTRAVENOUS
Marketing started: 20130301

FDA application: BLA125462

## Active ingredients

- EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2: 4500 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2: 3300 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2: 3000 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2: 600 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2: 5100 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2: 3000 [iU]/10mL
- EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2: 600 [iU]/10mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"60492-0075"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=60492-0075